Clinical Trial Update: Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients [NA]

View source ↗

Summary

Clinical trial update evaluating maraviroc (CCR5 antagonist) to reduce the incidence of Immune Reconstitution Inflammatory Syndrome in HIV-infected patients. St…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Immune Reconstitution Inflammatory Syndrome

Drugs mentioned

• Selzentry (Maraviroc)

Snippet

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Conditions: Immune Reconstitution Inflammatory Syndrome, HIV | NA | Status: UNKNOWN